...All right. Good afternoon, everyone, and thanks for joining us here at the SVB Securities Global Biopharma Conference. My name is Tom Smith. I'm one of the senior biotech analyst here at SVB Securities, and very happy to be hosting this next fireside chat with Keros Therapeutics. As a company with deep expertise in TGF-beta biology, three clinical stage assets, and a number of really interesting intrinsic and extrinsic data catalysts expected over the next 12 months that I'm sure we'll get into in more detail here. Joining us from the company is CEO, Jas Seehra. Jas, thanks for joining us. Jas Seehra ...